Arvanil

Synonyms: N-Vanillylarachidonamide
Arvanil(N-Vanillylarachidonamide)是一种混合型 CB1 受体和 TRPV1 受体激动剂,可下调 CD25、HLA-DR、CD134/OX40,阻滞 G1/S 期转换,并使 Akt 发生磷酸化,但不诱导细胞凋亡,从而抑制淋巴细胞活化并改善自身免疫性脑脊髓炎,可用于亨廷顿病、呕吐及多发性硬化的相关研究。
产品编号: MS-H28395 纯度: 99.1% CAS No.: 128007-31-8 分子式: C28H41NO3 分子量: 439.63
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mg (113.73mM * 200μL in Ethanol)
询价
3-5 天
5mg (113.73mM * 100μL in Ethanol)
询价
3-5 天

产品描述

Arvanil(N-Vanillylarachidonamide)是一种混合型 CB1 受体和 TRPV1 受体激动剂,可下调 CD25、HLA-DR、CD134/OX40,阻滞 G1/S 期转换,并使 Akt 发生磷酸化,但不诱导细胞凋亡,从而抑制淋巴细胞活化并改善自身免疫性脑脊髓炎,可用于亨廷顿病、呕吐及多发性硬化的相关研究。

生物实验数据

生物活性 Arvanil (N-Vanillylarachidonamide) is a mixed CB1 receptor and TRPV1 receptor agonist that downregulates CD25, HLA-DR, and CD134/OX40, blocks the G1/S phase transition, and induces Akt phosphorylation without inducing apoptosis, thereby inhibiting lymphocyte activation and ameliorating autoimmune encephalomyelitis, and it can be used for research related to Huntington's disease, emesis, and multiple sclerosis.
IC50 & Target

TRPV1

 

CB1

 

体外研究
(In Vitro)

Arvanil (10 μM; 48 h) 可强效抑制经 OKT3 刺激的外周血单个核细胞 (PBMCs) 的增殖,在 10 μM 浓度下抑制率达 75.3%,该效果优于相同浓度下的 anandamide 和辣椒素。
Arvanil (0.3-30 μM; 48 h) 以剂量依赖方式抑制经 CD3CD28 刺激的外周血单个核细胞 (hPBMCs) 的增殖,在 10 μM 浓度下抑制率达 64.0%,同时可降低 IFN-γ 的产生,但不影响该浓度下的 IL-5 水平。
Arvanil (3-10 μM; 48 h) 可抑制经 IL-2 刺激的小鼠 CTLL-2 细胞增殖,在 10 μM 浓度下可观察到显著抑制作用。
Arvanil (10 μM) 可抑制 OKT3 刺激的外周血单个核细胞 (hPBMCs) 中 CD4+ T 细胞上 CD25、HLA-DR 和 CD134/OX40 活化标志物的上调。
Arvanil (10 μM; 48 h) 不会在经 OKT3 刺激的外周血单个核细胞 (hPBMCs) 来源的 CD4+ T 细胞中诱导细胞凋亡。
Arvanil (10 μM; 48 h) 可阻断 OKT3 刺激的外周血单个核细胞 (hPBMCs) 的 G1/S 期转换。

Cell Proliferation Assay

Cell Line: murine CTLL-2 cells stimulated with interleukin-2 (IL-2)
Concentration: 3-10 μM
Incubation Time: 48 h
Result: Inhibited IL-2-stimulated CTLL-2 proliferation, with statistically significant inhibition observed at 10 μM (p<0.05); the inhibitory effect at 3 μM was less pronounced.

Cell Cycle Analysis

Cell Line: OKT3-stimulated hPBMCs
Concentration: 10 μM
Incubation Time: 48 h
Result: Increased G1-phase cells to 86% and reduced S-phase cells to 13%.
体内研究
(In Vivo)

Arvanil (2 mg/kg;腹腔注射; 单次) 可缓解亨廷顿病大鼠模型的运动过度症状 (活动增加、静息减少),该效应与苍白球谷氨酸含量升高相关,同时还能降低正常大鼠的自主活动能力。
Arvanil (2 mg/kg;腹腔注射;单次) 可降低正常大鼠的自主活动与探究行为,该效应与苍白球内 GABA 含量升高相关。
Arvanil (1-2 mg/kg;腹腔注射;M6G 处理前 15 分钟单次给予) 可通过激活 CB1 和 TRPV1 受体,剂量依赖性地抑制吗啡-6-葡糖苷酸诱导雪貂产生的恶心与呕吐反应;其中 2 mg/kg 剂量可显著减少恶心和呕吐发作次数,该效应可被上述两种受体的选择性拮抗剂逆转。
Arvanil (0.5 mg/kg;于实验性自身免疫性脑脊髓炎 (EAE) 诱导前 3 天和诱导后 3 天分 2 次给予) 处理可显著改善雌性 SJL/J 小鼠的实验性自身免疫性脑脊髓炎,使累积疾病指数降低 48.2%,峰值临床评分降低 56.7%,最大体重减轻率降低 66.8%,中枢神经系统炎性病灶减少 51.3%。

Animal Model: Sprague-Dawley (male, 3-4 months old, 300-400 g, bilateral intrastriatal injection of 375 nmol 3-nitropropionic acid per striatum, used 14 days post-lesion)
Dosage: 2 mg/kg
Administration: i.p.; single acute dose
Result: Significantly reduced increased ambulatory activity (F(1,21)=18.74, P < 0.0005).
Increased time spent in inactivity (F(1,21)=40.10, P < 0.0001).
Enhanced lesion-induced reductions in stereotypic activity (F(1,22)=21.91, P < 0.0001) and hole entries (F(1,22)=43.18, P < 0.0001).
Increased glutamate contents in the globus pallidus (F(1,21)=5.89, P < 0.05).
Did not reverse GABA, glutamate, or dopamine deficits in the caudate-putamen.
Animal Model: Sprague-Dawley (male, 3-4 months old, 300-400 g, bilateral intrastriatal injection of saline vehicle, allowed 14 days to recover)
Dosage: 2 mg/kg
Administration: i.p.; single acute dose
Result: Significantly reduced ambulatory activity, stereotypic activity, and number of hole entries.
Increased time spent in inactivity.
Increased GABA contents in the globus pallidus (F(1,19)=3.89, P < 0.05).
Tended to increase globus pallidus GAD activity.
Showed no effects on dopamine, DOPAC, TH activity, GABA, GAD activity, or glutamate contents in the caudate-putamen.
Animal Model: Mustela putorius furo (adult male, 900-1500 g)
Dosage: 1 mg/kg; 2 mg/kg
Administration: i.p.; single dose 15 min pre-M6G
Result: Reduced M6G-induced emetic episodes compared to M6G alone.
Dose-dependently reduced M6G-induced emetic episodes to a greater extent than the 1 mg/kg dose; this anti-emetic effect was reversed by pre-treatment with 5 mg/kg AM251 or 0.1 mg/kg IRTX, with emetic episode counts returning to levels not significantly different from M6G alone.
Reduced M6G-induced vomiting episodes from 1.8 to 0.8 (P < 0.05); this effect was reversed by 5 mg/kg AM251 (to 1.4 episodes, P < 0.05 vs arvanil alone) and completely abolished by 0.1 mg/kg IRTX (to 1.8 episodes, P < 0.05 vs arvanil alone).
Reduced M6G-induced tongue licking movements from 6.6 licks/h to 2.3 licks/h (P < 0.01 vs M6G); this effect was reversed by CB1 and TRPV1 antagonists.
Dose-dependently reduced voluntary activity minutes in a 1-hour observation period; this sedative effect was not reversed by AM251 or IRTX.
Pre-treatment with 5 mg/kg AM630 did not reduce the anti-emetic effects of arvanil (3.5 emetic episodes vs 1.8 emetic episodes with arvanil alone, P > 0.05).
性状 液体
颜色 Colorless to light yellow

化学信息

分子量 439.63
分子式 C28H41NO3
CAS No. 128007-31-8
别名 N-Vanillylarachidonamide

储存&溶解度

溶解度信息
Ethanol: 8 mg/mL (18.2 mM), Sonication is recommended.
储存方式

Solution, -20°C, 2 years

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础